Pharma & Mergers

Mergers

The EU Commission sends three separate statements of objections to companies alleging procedural breaches of the EU Merger Regulation (Merck / Sigma-Aldric, GE / LM Wind, Canon / Toshiba Medical Systems)
Van Bael & Bellis (Brussels)
On 6 July 2017, the European Commission sent three separate statements of objections (“SO”) to companies alleging procedural breaches of the EU Merger Regulation. Provision of misleading information The first SO concerns the Merck/Sigma-Aldrich transaction, which was conditionally cleared by (...)

The EU Commission sends statements of objection to three undertakings regarding possible breach of EU merger procedural rules (Merck / Sigma-Aldrich, General Electric / LM Wind and Canon / Toshiba)
DG COMP (Brussels)
Mergers: Commission alleges Merck and Sigma-Aldrich, General Electric, and Canon breached EU merger procedural rules* The Commission has sent three separate Statements of Objections to Merck and Sigma-Aldrich, General Electric and Canon alleging they breached EU merger rules: General Electric, (...)

The French Competition Authority adopts an innovative merger decision in the health care institution sector (Elsan / MPP)
Simmons & Simmons (Paris)
The French Competition Authority (FCA) has adopted an innovative merger decision in the health care institution sector, assessing not only the effects of the operation on medical services (diagnostic and treatments), but also the effects on non-medical ancillary services. An innovative merge (...)

The EU Commission clears a merger, subject to remedies, in the pharmaceutical sector (St Jude Medical / Abbott Laboratories)
DG COMP (Brussels)
Mergers: Commission approves acquisition of St Jude Medical by Abbott Laboratories, subject to conditions* The European Commission has approved under the EU Merger Regulation the proposed acquisition of St Jude Medical by Abbott Laboratories, both US based companies that develop and market (...)

The EU Commission clears a merger, subject to remedies, in the pharmaceutical sector (Boehringer Ingelheim /Sanofi)
DG COMP (Brussels)
Mergers: Commission clears acquisition of Boehringer Ingelheim’s consumer health business by Sanofi, subject to conditions* The European Commission has approved under the EU Merger Regulation the proposed acquisition of the consumer health business of Germany’s Boehringer Ingelheim by Sanofi of (...)

The Dutch Competition Authority clears a merger between two rivals in the pharmaceutical sector (DA group / Holland Pharma)
Netherlands Authority for Consumers & Markets (The Hague)
ACM clears acquisition of DA group by rival Holland Pharma* The Netherlands Authority for Consumers and Markets (ACM) has cleared the acquisition of the DA group by Holland Pharma Exploitatie B.V. Both Holland Pharma and DA are wholesale companies that trade in drugstore items. In addition, DA (...)

The Romanian Competition Authority clears a merger in the pharmacies sector (Centrofarm / Help Net Farma)
Romanian Competition Council (Bucharest)
The Competition Council has authorized the takeover of 19 pharmacies Centrofarm by Help Net* The Competition Council has authorized the take over of 19 pharmacies Centrofarm by Help Net Farma SA. By this transaction, Help Net take over the 19 pharmacies Centrofarm from 10 localities: (...)

The Chinese MOFCOM fines several undertakings for breaches of merger notification rules (FJEI / FPID / Nanjing Puzhen / Bombardier Sweden / BestTv / Microsoft)
AnJie Law (Beijing)
,
AnJie Law (Beijing)
Warning from MOFCOM: Second Wave of Penalties Imposed for Breaches of Concentration Notification Rules* On September 29th 2015, the Ministry of Commerce of the P.R.C (“MOFCOM”) published four administrative decisions on penalties for illegal activities involved in the concentration of (...)

The UK Competition Authority orders licensing remedy to meet concerns over horizontal unilateral effects resulting from a merger in the personal lubricants market (Reckitt Benckiser / Johnson & Johnson)
Herbert Smith Freehills (Brussels)
Introduction and background On 4 November 2015, the UK Competition and Markets Authority ("CMA") accepted final undertakings from Reckitt Benckiser Group plc ("RB") and Johnson & Johnson ("J&J") in relation to RB’s proposed acquisition from J&J of the K-Y brand of personal lubricant (...)

The UK Competition Authority imposes remedies to clear an acquisition in the market of personal lubricants (Reckitt Benckiser / Johnson & Johnson)
British Competition Authority - CMA (London)
CMA orders remedy to meet concern over lubricants merger* The CMA has found that Reckitt Benckiser’s anticipated acquisition of the K-Y brand could lead to higher prices for personal lubricants. In its final report published today, the Competition and Markets Authority (CMA) has concluded the (...)

The FTC challenges a merger in regional markets for sterilization of products using radiation based on future competition concerns (Steris / Synergy Health)
Doyle, Barlow & Mazard (Washington DC)
FTC Challenges Deal Based on Future Competition Concerns* On May 29, 2015, the Federal Trade Commission (“FTC”) issued an administrative complaint alleging that Steris Corporation’s (“Steris”) proposed $1.9 billion acquisition of Synergy Health plc (“Synergy”) would violate the antitrust laws by (...)

The UK Competition and Markets Authority provisionally judges that an anticipated merger between pharmaceuticals enterprises could lead to higher prices in the personal lubricants market (Reckitt Benckiser / Johnson & Johnson)
British Competition Authority - CMA (London)
CMA sets out provisional concerns over lubricants merger* The CMA has provisionally found that Reckitt Benckiser’s anticipated acquisition of the K-Y brand could lead to higher prices for personal lubricants. Reckitt Benckiser (RB) and Johnson & Johnson (J&J) supply personal lubricants (...)

The EU Commission conditionally clears a merger following an in-depth investigation (Zimmer / Biomet)
DG COMP (Brussels)
,
DG COMP (Brussels)
Introduction On 30 March 2015, the European Commission conditionally cleared Zimmer’s acquisition of Biomet, following an in-depth investigation. Zimmer and Biomet are two of the five leading competitors in the medical implants industry. The transaction was initially notified on 3 June 2014, (...)

The Competition Commission of Singapore takes a provisional decision to block a proposed acquisition in the radiology and imaging services sector (RadLink-Asia / Fortis Singapore)
Allen & Gledhill (Singapore)
,
Allen & Gledhill (Singapore)
On 16 March 2015, the Competition Commission of Singapore (“CCS”) announced that it had taken a provisional decision to block the proposed acquisition of RadLink-Asia Pte Limited (“RadLink”), a wholly owned subsidiary of Fortis Healthcare Singapore Pte. Limited (“Fortis Singapore”) by Medi-Rad (...)

Mergers in the pharmaceutical sector: An overview of EU and national case law
Arnold & Porter Kaye Scholer (Brussels)
In the past ten years or so, e-Competitions’ Bulletin has regularly reported about pharmaceutical merger control decisions or judgments from various jurisdictions in the world. Many of these cases involved remedies that were meant to address the antitrust concerns that the competent competition (...)

The Pakistan Competition Commission clears a merger, subject to remedies, in the pharmaceutical sector (Novartis / GlaxoSmithKline)
Competition Commission of Pakistan (Islamabad)
CCP approves acquisition of global vaccine business (excluding influenza business except in China) by GSK from Novartis* The Competition Commission of Pakistan (CCP) has approved acquisition of the global vaccines business (excluding influenza business except in China) of Novartis AG by (...)

The Pakistan Competition Commission clears an acquisition, following an in-depth investigation, in the pharmaceutical sector (Novartis / GlaxoSmithKline)
Competition Commission of Pakistan (Islamabad)
The Competition Commission clears phase II review of the proposed acquisition by novartis ag of the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline plc* ISLAMABAD, MONDAY, 09 FEBRUARY 2015: The Competition Commission of Pakistan (...)

The EU Commission conditionally approves deals in the pharmaceutical sector extending its analysis of pipeline pharmaceutical products (GSK / Novartis)
DG COMP (Brussels)
,
DG COMP (Brussels)
,
DG COMP (Brussels)
"Protecting the drugs of tomorrow : competition and innovation in healthcare"* In a nutshell : In Novartis/GSK Oncology, the Commission extended its analysis of pipeline pharmaceutical products beyond those that are in advanced stages of development (phase III), to fully assess the (...)

The EU Commission conditionally approves a three part deal in the pharmaceutical sector (GSK / Novartis)
Van Bael & Bellis (Brussels)
On 28 January 2015, in two separate decisions, the European Commission conditionally approved a complex transaction between pharmaceuticals producers GlaxoSmithKline (GSK) and Novartis that will result in: (i) GSK’s acquisition of Novartis’ human vaccines business; (ii) the formation of a joint (...)

The Competition Commission of India directs for the first time a divestiture of assets in a merger case (Sun-Ranbaxy)
Shardul Amarchand Mangaldas & Co (Mumbai)
,
Economic Laws Practice (Mumbai)
Introduction The Competition Commission of India (“CCI”) for the first time has directed divestitures of assets, before granting its final approval, in a combination relating to merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharmaceutical Industries Limited (“Sun Pharma”) (referred (...)

The Competition Commission of Pakistan opens an in-depth investigation on a merger in the pharmaceutical sector regarding the market of meningococcal vaccines (Novartis / GlaxoSmithKline)
Competition Commission of Pakistan (Islamabad)
CCP opens second phase review on the proposed acquisition of vaccines business (excluding influenza vaccines business except in china) of Novartis ag by Glaxosmithkline plc.* Islamabad, Thursday, 13 November 2014: The Competition Commission of Pakistan (CCP) in concluding the first phase (...)

The UK Competition and Markets Authority refuses to apply the failing firm defence to clear a merger in phase II (Alliance / IBA)
St John’s Chambers (Bristol)
United Kingdom Merger Control: Recent Developments in the Failing Firm Defence* On 15 August 2014, the Competition and Markets Authority (“CMA”) approved Alliance Medical Group’s completed acquisition of IBA Molecular’s radioactive medical tracer business. Although IBA’s business was loss-making, (...)

The UK Competition and Markets Authority clears an acquisition on the adherence packaging market (Omnicell / SurgiChem)
British Competition Authority - CMA (London)
The Competition and Markets Authority (CMA) has cleared Omnicell/MTS’s proposed acquisition of SurgiChem.* This confirms the CMA’s provisional decision which was published last month and has been made by a group of independent CMA panel members. Omnicell, Inc./MTS Medication Technologies, Inc. (...)

The UK’s Business secretary proposes new safeguards to counteract the threat of foreign takeovers to the national interest (Pfizer/AstraZeneca)
UEA law school - Centre for Competition Policy
Pfizer/AstraZeneca and the Public Interest: Do Vince Cable’s Foreign Takeover Proposals Prescribe the Right Medication?* When US pharmaceutical giant Pfizer sought to acquire its UK-listed counterpart AstraZeneca earlier this year, discussion centred around the supposed adverse impact that the (...)

The New Zealand Commerce Commission publishes statement of preliminary issues following merger notification on the market for pharmacy wholesaling
New Zealand Commerce Commission (Wellington)
Press releases published on New Zealand Commerce Commission Statement of preliminary issues published for CDC Pharmaceutical and Pharmacy Wholesalers merger* CDC Pharmaceuticals and Pharmacy Wholesalers (Central) seek clearance to merge The Commerce Commission has received a joint (...)

The Polish Competition Authority issues conditional clearance for concentration in pharmaceutical sector (Neuca/ACP Pharma)
WKB Wierciński Kwieciński Baehr (Warsaw)
In the decision of 31 March 2014, the President of the Office for Competition and Consumer Protection (hereinafter referred to as the “OCCP President”) approved concentration consisting of Neuca taking control over ACP Pharma. However, Neuca must sell one of its wholesalers located in Bydgoszcz (...)

The Chinese MOFCOM conditionally approves an acquisition in the biotechnology sector (Thermo Fisher / Life Technologies)
First Principles Economics (London)
On Tuesday 14th January 2014 MOFCOM conditionally cleared the acquisition of Life Technologies Corporation (“Life Technologies”) by Thermo Fisher Scientific Inc. (“Thermo Fisher”). The review process took 6 months from initial notification, which is relatively quick for an intervention decision by (...)

The Australian Competition and Consumer Commission conditionally approves the proposed acquisition in life science sector (Life Technologies / Thermo Fisher Scientific)
Australian Competition and Consumer Commission (Canberra)
ACCC conditionally approves the proposed acquisition of Life Technologies by Thermo Fisher* The Australian Competition and Consumer Commission has announced that it will not oppose the proposed acquisition of Life Technologies Corporation by Thermo Fisher Scientific Inc after competition (...)

The US FTC issues final changes to the premerger notification rules that require companies in the pharmaceutical industry to report certain proposed acquisitions of exclusive patent rights to the FTC and the DoJ for antitrust review
University of Michigan
Is the FTC Picking on the Pharmaceutical Industry Through New HSR Rules?* Effective December 16, 2013, Hart-Scott-Rodino (HSR) coverage of exclusive licenses of patents will change. As HSR practitioners know well, the Federal Trade Commission’s Premerger Notification Office (PNO) has (...)

The Danish Competition Council conditionally approves acquisition on the market for veterinary drugs (Vilomix / Hatting-KS)
Danish Competition and Consumer Authority (Copenhagen)
Danish Competition Council approves Vilomix Holding A/S’ acquisition of A/S Hatting-KS conditional on commitments* On October 23th 2013 the Danish Competition Council (“DCC”) approved Vilomix Holding A/S’ (Vilomix) acquisition of A/S Hatting-KS (Hatting). The DCC decision is conditional on a (...)

The Chinese MOFCOM conditionally approves the EUR 3 billion acquisition of a medical technology company (Baxter & Gambro)
King & Wood Mallesons (Beijing)
MOFCOM Conditionally Cleared Baxter’s $4 Billion Acquisition of Gambro* On August 13, 2013, China’s Ministry of Commerce (MOFCOM) announced on its website that it has conditionally approved the $4 billion acquisition of Swedish medical technology company Gambro AB by Baxter International. (...)

The Chinese MOFCOM grants a clearance on the proposed acquisition of a Swedish equipment manufacturer by an American healthcare company (Baxter & Gambro)
AnJie Law (Beijing)
MOFCOM conditionally approves Baxter’s acquisition of Gambro* On 8 August 2013, China’s Ministry of Commerce ("MOFCOM") granted a clearance on the proposed acquisition of the Swedish dialysis equipment manufacturer Gambro AB ("Gambro") by its US rival healthcare company Baxter ("Baxter") in (...)

The Irish Competition Authority clears a merger between a pre-wholesaler and a wholesaler of pharmaceutical, healthcare and veterinary products (Uniphar & CMR)
Irish Competition Authority (Dublin)
Competition Authority clears proposed acquisition of CMR by Uniphar* The Competition Authority has cleared the proposed transaction whereby Uniphar plc would acquire Cahill May Roberts Limited. The transaction was notified by the parties under the Competition Act 2002 on 12 December 2012 and (...)

The Portuguese Competition Authority imposes record fine for gun-jumping (Farminveste)
Van Bael & Bellis (Brussels)
,
Van Bael & Bellis (Brussels)
At the end of December 2012, the Portuguese Competition Authority fined the Portuguese National Pharmacy Association and two subsidiaries of Portuguese company Farminveste € 150,000 for implementing their acquisition of pharmaceutical company ParaRede-Glintt without obtaining prior merger (...)

The German Competition Authority prohibits joint venture in chemicals trading sector (Chemie-Vertrieb)
European Commission
Germany: The Bundeskartellamt prohibits Joint Venture in Chemicals Trading Sector* On 21 November 2012, the Bundeskartellamt (BKartA) issued a prohibition decision concerning a joint venture of two chemicals trading companies. The joint venture in question, CVH Chemie-Vertrieb GmbH & Co (...)

The US FTC proposes revisions to the premerger notification rules for pharmaceutical patent licensing transactions
Crowell & Moring (Washington)
The FTC’s Proposed Revisions to the Premerger Notification Rules for Pharmaceutical Patent Licensing Transactions* Recent developments On August 13, 2012, the Federal Trade Commission (“FTC”) released proposed amendments to the Hart-Scott-Rodino (“HSR”) premerger notification rules relating to the (...)

US antitrust agencies propose new Hart-Scott-Rodino merger control rules to require enhanced reporting of pharma, biological and diagnostic licenses
Thompson Hine (New York)
New FTC/DOJ position will require heightened regulatory reporting of pharma, biological and diagnostic licenses* The Federal Trade Commission and Department of Justice recently announced revisions to the Hart-Scott-Rodino (HSR) Act’s premerger notification rules to require enhanced reporting of (...)

The Cyprus Commission for the Protection of Competition imposes a fine to an unnotified concentration in the pharmaceutical sector (Papaellinas / Sophocles Demetriades)
Neocleous (Nicosia)
Factual background The present case concerns the possible breaches of articles 9 and 13 of the Law on Control of Concentrations of Enterprises Laws of 1999 and 2000. The concentration in question was brought about following the conclusion of the Share Purchase Agreement dated 17.02.2010, (...)

The President of the Office of Competition and Consumer Protection clears a merger on the pharmaceutical market in Poland under sell-off conditions applicable to three medicaments (Polpharma/Polfa)
Markiewicz & Sroczynski
I. The Facts On 26 October 2011, Polpharma S.A. with its seat in Starogard Gdanski (“Popharma”), a leading Polish producer of pharmaceutical products and active ingredients, notified the President of the Office of Competition and Consumer Protection (“OCCP”) of its intention to acquire control over (...)

A US Court of Appeals rejects the FTC’s attempt to identify a relevant product market in a pharmaceuticals related merger (Lundbeck)
Cleveland-Marshall School of Law
FTC v. Lundbeck: Why, God, Why?* What really has the world come to when a merger to monopoly followed by a 1300% price increase survives Section 7 challenge? That, sadly, seems to be the final result in Federal Trade Commission v. Lundbeck, which the Eighth Circuit affirmed last Friday. (...)

The US Court of Appeals for the 8th Circuit upholds a lower court’s finding that the FTC failed to show the relevant market in a case concerning the acquisition of two drugs treating a similar heart defect (Lundbeck)
Scharf Banks Marmor (Chicago)
What Is a Relevant Market Anyhow?* The Eight Circuit, in FTC v. Lundbeck, Inc., No. 10-3458/3459 (Aug. 19, 2011), upheld the district court’s finding that the FTC failed to show a relevant market, and thus was unable to challenge the acquisition of the drug NeoProfen. It already owned a drug (...)

The EU Commission clears a joint venture in the pharmaceutical sector, after examining possible coordination between Chinese State-owned companies (DSM / Sinochem)
Van Bael & Bellis (Brussels)
In a decision of 19 May 2011, the European Commission unconditionally cleared the creation of a joint venture between Dutch pharmaceutical company DSM and Chinese State-owned conglomerate Sinochem. The joint venture will be active primarily in antibiotics and other anti-infective products. In (...)

The European Commission waives commitment imposed on a merger in the DNA probes sector (Hoffmann-La Roche/Boehringer Mannheim)
Van Bael & Bellis (Brussels)
In a recently published decision of 3 May 2011, the European Commission waived certain commitments imposed as a condition of its approval of the acquisition of Boehringer Mannheim by Hoffman-La Roche in February 1998. In the 1998 decision, the Commission found that Hoffman-La Roche’s dominant (...)

A US District Court denies FTC request for a preliminary injunction in medical laboratory merger case (LabCorp)
Skadden, Arps, Slate, Meagher & Flom (New York)
,
Skadden, Arps, Slate, Meagher & Flom (Palo Alto)
,
Kirkland & Ellis (New York)
In a decision broadly critical of the Federal Trade Commission’s case challenging the acquisition of Westcliff Medical Laboratories, Inc., a medical laboratory company, by Laboratory Corporation of America (LabCorp), Judge Andrew Guilford of the U.S. District Court for the Central District of (...)

A US Court of Appeals rejects antitrust lawsuit that challenged premerger planning and information exchanges between two health insurers (Omnicare/UnitedHealth)
Jones Day (Washington DC)
,
Jones Day (Houston)
This article has been selected for the business category, mergers section of the 2012 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Last week the U.S. Court of Appeals for the Seventh Circuit rejected an antitrust lawsuit by institutional pharmacy (...)

The US FTC and the State of Minnesota appeal the district court’s decision on relevant market issue in a pharmaceutical merger case (Lundbeck)
Cleveland-Marshall School of Law
Some Reflections on the Lundbeck Appeal: Will Pharmaceuticals Get a Blanket Antitrust Immunity? And Is Quality Competition No Longer Protected by Antitrust?* A decision to watch for this year is the Eighth Circuit’s pending consideration of FTC v. Lundbeck, Inc., 2010-2 Trade Cases ¶77,160; 2010 (...)

The UK Office of Fair Trading holds that merger between two laboratories does not require referral to the Competition Commission under the Enterprise Act 2002 (Reckitt Benckiser)
University of Southampton
I. Introduction The Office of Fair Trading (OFT) has decided the merger between Reckitt Benckiser Inc. (Reckitt) and Combe Incorporated (Combe) will not substantially lessen competition in the market for the supply of certain pharmaceutical products. The merger does not have to be referred to (...)

The Netherlands Competition Authority clears pharmacies merger, subject to divestiture of four pharmacies (Brocacef/Lloyds Nederland)
Liberty Global (Amsterdam)
The merger The merger involved the acquisition of Lloyds Nederland BV («Lloyds») by Brocacef Holding NV («Brocacef»). Lloyds operated 63 pharmacies in the Netherlands at the time of the decision by the Netherlands competition authority («NMa») and is a subsidiary of the German group Celesio AG. (...)

The China’s State Council approves the merger between the largest pharmaceutical and healthcare group under the State-Assets Supervision and Administration Commission and a centrally-administered state-owned enterprise (CNSC / Sinopharm)
University of Melbourne
,
China Competition Bulletin (Beijing)
,
Institute of American Studies (Beijing)
The China National Service Corporation for Chinese Personnel Working Abroad (CNSC, 中 国出国人员服务总公司), a centrally-administered state-owned enterprise, has merged with the China National Pharmaceutical Group Corporation (Sinopharm, 国药集团). The State Council approved the merger. Sinopharm is the largest (...)

The US District Court for the District of Minnesota dismisses FTC complaint seeking divestiture and disgorgement remedy in consummated acquisition in the healthcare industry (Lundbeck)
Jones Day (Washington DC)
,
Jones Day (Washington DC)
,
Jones Day (Washington DC)
In a decision that was filed under seal in late August but released publicly just last week, the U.S. District Court for the District of Minnesota dismissed with prejudice the complaint filed by the Federal Trade Commission (FTC) and the State of Minnesota challenging the already-consummated (...)

A US district court rules against the FTC holding that it has failed to prove the relevant market in pharmaceutical merger case (Lundbeck)
Wolters Kluwer (Riverwoods)
FTC Loses Suit against Drug Maker over 2006 Acquisition* The Federal Trade Commission recently suffered a significant setback in its merger enforcement efforts when the federal district court in Minneapolis rejected an action brought by the agency along with the State of Minnesota against (...)

The US DoJ and FTC issue new merger guidelines suggesting increased focus on deals in high tech and pharmaceutical sectors
Gibson Dunn (New York)
New U.S. Merger Guidelines Suggest Increased Focus on Deals in High Tech and Pharmaceutical Sectors* In August 2010, the U.S. antitrust agencies released the final version of their revised Horizontal Merger Guidelines, which they use to analyze the competitive implications of mergers between (...)

The Chinese MOFCOM conditionally clears a merger in the pharmaceutical industry (Novartis / Alcon)
Linklaters (Beijing)
,
,
Linklaters (Brussels)
On 13 August 2010, the Ministry of Commerce of the People’s Republic of China (“MOFCOM”) issued a conditional approval for the proposed acquisition of Alcon (“Alcon”) by Novartis AG (“Novartis”). The decision was issued after a merger review of just under four months (one month for Phase One review (...)

The Chinese MOFCOM imposes conditions on merger in pharmaceutical industry (Novartis / Alcon)
Jones Day (Beijing)
,
Gibson Dunn (Hong Kong)
,
Jones Day (Beijing)
After a four-month review, on 13 August 2010, China’s Ministry of Commerce (“MOFCOM”) authorized Novartis‘ acquisition of Alcon subject to conditions. Taking different approaches than one would see in the U.S. or European Union, MOFCOM’s decision is notable for the demanding view it takes of (...)

The EU Commission conditionally clears a merger between a German generic pharmaceutical company and an Israeli pharmaceutical company (Ratiopharm / Teva)
J G Associates (Brussels)
"Mergers: main developments between 1 May and 31 August 2010"* On 3 August the Commission approved the proposed acquisition of the German generic pharmaceutical company Ratiopharm by Teva, Israel. The decision is conditional upon the divestment of 15 products in the Netherlands and one in (...)

A US District Court reaffirms importance of market definition in antitrust merger analysis (Golden Gate Pharmacy / Pfizer)
Skadden, Arps, Slate, Meagher & Flom (Washington DC)
,
Skadden, Arps, Slate, Meagher & Flom (New York)
On April 16, 2010, Judge Maxine M. Chesney of the U.S. District Court for the Northern District of California dismissed a complaint raising a private antitrust challenge to the merger of Pfizer, Inc. and Wyeth Pharmaceuticals, because she concluded that the complaint failed sufficiently to (...)

The EU Commission conditionally clears the acquisition of a Belgian pharmaceuticals company by a US competitor (Abbott / Solvay Pharmaceuticals)
J G Associates (Brussels)
"Merger: main developments between 1 January and 30 April 2010" On 11 February the Commission approved the proposed acquisition of Solvay Pharma (Belgium) by Abbott Laboratories (USA). The decision is conditional upon the divestment of the Cystic Fibrosis testing business of Solvay Pharma’s (...)

The US FTC imposes remedies before clearing a merger affecting multiple markets for animal health and pharmaceutical products (Pfizer / Wyeth)
Akin Gump Strauss Hauer & Feld (Dallas)
The FTC entered into a consent agreement with Pfizer Inc. and Wyeth, requiring divestiture of one entity’s U.S. operations in over 20 markets for various animal health and pharmaceutical products. The consent order, established on January 25, 2010, sets forth the divestiture of Wyeth’s U.S. (...)

The Romanian Competition Council carries out dawn raid on suspicion of “gun-jumping” infringement (Advent, Ozone Laboratories)
Van Bael & Bellis (Brussels)
According to a press release of 19 November 2009, the Romanian Competition Council carried out unannounced inspections (so-called “dawn raids”) at the premises of Advent and Ozone Laboratories, in the framework of its investigation of a notified merger between these two companies. Although the (...)

The Chinese MOFCOM conditionally clears major overseas transaction in the pharmaceuticals industry (Pfizer / Wyeth)
WilmerHale (Beijing)
,
WilmerHale (Beijing)
China’s Ministry of Commerce (MOFCOM) has just cleared two major overseas transactions, Pfizer’s acquisition of Wyeth in the pharmaceuticals industry and General Motors’ reacquisition of elements of auto parts manufacturer Delphi on September 28 and 29, respectively. Both clearances were subject (...)

The European Commission considers generic competition and pipeline products in the human-health pharmaceutical sector in unconditionally clearing the merger (Pfizer/Wyeth)
Van Bael & Bellis (Brussels)
On 17 July 2009, the European Commission approved the acquisition by Pfizer Inc. USA («Pfizer») of Wyeth USA. In its decision, the Commission identified substantial horizontal overlaps in the parties’ human health pharmaceutical operations, as well as in the parties’ animal health operations, (...)

The European Commission conditionally approves an acquisition in the pharmaceuticals and health care products (Pfizer / Wyeth)
J G Associates (Brussels)
"Mergers: main developments between 1 May and 31 August 2009"* On 7 July 2009 the Commission approved the proposed acquisition of the US pharmaceutical and health care products company Wyeth by the US global pharmaceutical company Pfizer. The approval is conditional upon Pfizer‘s commitment to (...)

The US FTC files a complaint to stop a proposed merger between two leading producers of plasma-derivative protein therapies (CSL / Talecris)
Jones Day (Washington DC)
Just two weeks after the FTC filed a complaint seeking an injunction to stop the proposed $3.1 billion acquisition by Australia-based CSL Limited of Talecris Biotherapeutics Holding Corporation, the parties have withdrawn their plans for a merger. The announcement, made on June 8, 2009, came (...)

As part of a second phase investigation, the Swedish Competition Authority cleared a merger between the only two companies selling the same active pharmaceutical ingredient in the OTC market in Sweden (GlaxoSmithKline Dungarvan /AstraZeneca Tika)
Maersk (Copenhagen)
The parties to the transaction, i.e., GlaxoSmithKline Dungarvan ("GSK") and AstraZeneca Tika ("AZT") are active in Sweden within the field of, inter alia, consumer health. The Swedish Competition Authority ("SCA") divided the sale of pharmaceuticals into the following three markets; personal (...)

The Macedonian Administrative Court confirms a merger prohibition decision in the market for retail distribution of pharmaceutical products (Zegin)
Faculty of Law - University of Macau
On 1 June 2006 Zegin, leading distributor of the pharmaceuticals on the territory of Skopje municipality agreed with two other retail distributors of medicines - Alkaloid and Pharma Corp. to acquire joint control over City Pharmacy in Skopje , which owned a network of pharmacies in the (...)

The European Commission gives conditional clearance to an acquisition in the production of generic medicines (Teva/Barr Pharmaceuticals)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Mergers: main developments between 1 September and 31 December 2008"* On 19 December the Commission gave conditional approval to the proposed acquisition of Barr Pharmaceuticals of the US by Teva Pharmaceutical Industries of Israel. Both companies produce generic medicines. To remedy the (...)

The US FTC seeks disgorgement remedy in challenge against pharma company for illegally acquiring drugs used to treat premature babies with life-threatening heart condition (Ovation)
Skadden, Arps, Slate, Meagher & Flom (Washington DC)
,
The Brattle Group (New York)
Continuing a trend of increasing aggressiveness in antitrust enforcement, the Federal Trade Commission (FTC) is seeking disgorgement in a challenge to Ovation Pharmaceutical Inc.’s acquisition of the drug NeoProfen®, filed in the Minnesota District Court on Dec. 16, 2008. In the past, the FTC has (...)

The US FTC places a price cap on intra-company prices as a condition precedent to clearing a merger in the market for iron sucrose administrated intravenously (Fresenius / Daiichi)
Weil, Gotshal & Manges (Washington)
,
US Federal Trade Commission (FTC) (Washington DC)
On September 15, 2008, the FTC announced that it challenged a manufacturing, distribution, and supply agreement between Fresenius Medical Care Ag & Co. KGaA (Fresenius) and Daiichi Sankyo Company, Ltd. (“Daiichi”) based on allegations that the proposed transaction would violate U.S. (...)

The Polish Competition Authority adopts a more economic approach to antitrust law as applied to pharmaceuticals (Richter Gedeon / Polpharma case)
Dentons (Warsaw)
,
Dentons (Warsaw)
Over the last few years, seldom did we have a chance to observe the Chairperson of the Polish Office for Competition and Consumer Protection (“UOKiK”) commenting broadly on the definition, structure or mechanisms of pharmaceutical markets. How surprising it was to find that in the decision of 3 (...)

The Estonian Competition Authority issues its first merger prohibition taking into account both previous acquisitions and potential future acquisitions in the pharmacy services sector (Terve Pere Apteek / Saku Apteek)
Jesse & Kalaus (Tallinn)
On 8 May 2008, the Director General of the Estonian Competition Authority (hereinafter the “ECA”) adopted a decision on the prohibition of the proposed acquisition of control over OÜ Saku Apteek (hereinafter “Saku Apteek”) by Terve Pere Apteek OÜ (hereinafter “TPA”). Since this is the first decision (...)

The Estonian Competition Authority raises doubt on its discretion to initiate in-depth merger investigations (Terve Pere Apteek/Saku Apteek)
Jesse & Kalaus (Tallinn)
On 8 January 2008 the Director General of the Estonian Competition Authority (“ECA”) adopted a decision on the initiation of supplementary proceedings (so-called in-depth investigation) with respect to a concentration whereby Terve Pere Apteek OÜ (“TPA”) would acquire control over OÜ Saku Apteek (...)

The European Commission conditionally clears a merger in the human and animal healthcare sector (Schering-Plough / Organon BioSciences)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Mergers: Main developments between 1 September and 31 December 2007"* On 11 October the Commission cleared the proposed acquisition of Organon BS of the Netherlands, a subsidiary of Akzo Nobel active worldwide in human and animal health, by the global pharmaceutical company Schering-Plough (...)

The European Commission conditionally clears a merger in the healthcare nutrition products sector (Nestle/Novartis)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Merger control: Main developments between 1 May and 31 August 2007"* In June the Commission approved the proposed acquisition of Novartis‘ Medical Nutrition business by Nestle. The approval was granted subject to the fulfilment of certain conditions. Nestle is active in the production, (...)

The Bulgarian Competition Authority unconditionally clears a foreign-to-foreign pharmaceutical merger (AstraZeneca/MedImmune)
US Federal Trade Commission (FTC)
In yet another foreign-to-foreign merger case, the Bulgarian Commission for the Protection of Competition (CPC or the Commission) issued a clearance decision neatly summing up the current state-of-play in terms of competition assessment of the pharmaceutical markets in Bulgaria. Following its (...)

The US FTC seeks divestiture of rights and assets to five different medications before approving a merger, which would affect the markets for generic injectable pharmaceuticals (Hospira / Mayne)
Akin Gump Strauss Hauer & Feld (Dallas)
The FTC entered into a consent decree with Hospira Inc. and Mayne Pharma Ltd. on May 21, 2007 imposing divestitures on the firms prior to clearing their merger. The consent decree required Mayne to divest its current business in one type of generic pharmaceuticals, as well as the assets (...)

The Portuguese Competition Authority clears a merger between a pharmacist and a wholesale and retail pharmacy group (Alliance/Unichem)
Morais Leitão, Galvão Teles, Soares da Silva & Associados (Porto)
,
Morais Leitão, Galvão Teles, Soares da Silva & Associados (Porto)
I. Introduction On December 23, 2005, the Portuguese Competition Authority (PCA) was notified of a concentration under which Alliance Santé Europe, S.A. (Alliance Santé), Farmindústria – Investimentos, Participações e Gestão, S.A. (Farmindústria) and José de Mello Participações II, SGPS, SA (JMP) (...)

The Brussels Court of Appeal gives its opinion on the relationship between merger control and the Belgian equivalents of Art. 101 and 102 TFEU in what may be its last preliminary ruling (Rocco)
Altius (Brussels)
,
Altius (Brussels)
On 15 December 2006, the Brussels Court of Appeal ruled on the relationship between the merger control rules and the general rules on restrictive practices. The court’s judgment followed a request for a preliminary ruling to the Court from the Commercial Court of Namur. Background The (...)

The UK Office of Fair Trading clears a merger in the retail pharmacy services sector, subject to the divestment of four retail pharmacies (Admenta Lloyds/IPCC)
Eli Lilly and Company (London)
The operation Lloyds is owned by Admenta Holdings Limited, a subsidiary of the German company Celesio AG, which also owns the pharmaceutical wholesaler AAH. Independent Pharmacy Care Centres plc (IPCC) comprises 34 retail pharmacies and one drug store (the latter does not have an NHS (...)

The Spanish Competition Authority conditionally clears in phase II a merger in the wholesale distribution to pharmacy stores sector (Cofares/Hefame)
RBB Economics
The operation The operation involved the merger of Cofares and Hefame to create a new wholesale distributor of pharmacy products. Both Cofares and Hefame specialised in the wholesale distribution of pharmacy and parapharmacy products. They also provided other complementary services to (...)

The European Commission approves, subject to divestiture, an acquisition in the insurance sector (Gerling/Talanx)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Mergers — Main developments between 1 January and 30 April 2006"* On 5 April the proposed acquisition of the German insurance group Gerling by the insurer Talanx was approved. Talanx Aktiengesellschaft (‘Talanx‘) is a German holding company. Its subsidiaries offer life and non-life insurances to (...)

The UK Office of Fair Trading clears a merger in the market for the supply of retail pharmacy services, subject to the divestment of a large number of stores (Boots/Alliance Unichem)
Added Value Capital Partners (AVCP)
The operation Boots operates 1,423 health and beauty stores in the UK and operates pharmacies in 1,350 of these stores. It intended to acquire Alliance UniChem, an international pharmaceutical distribution company, which operates 958 pharmacies in the UK. The market(s) The OFT considered the (...)

An Estonian Court of appeal confirms the right of third parties to challenge merger decisions, but upheld the Competition Authority’s merger clearance concerning the acquisition of a company controlling a chain of pharmacies by an Estonian dominant wholesaler of pharmaceuticals (Parimex Invest/Magnum Medical)
COBALT Legal
On 14 June 2005, the Tallinn Circuit Court (a court of appeal) issued a judgment upholding the Estonian Competition Authority’s (ECA) merger clearance concerning the acquisition of OÜ Parimex Invest, a company controlling a chain of pharmacies, by AS Magnum Medical, an Estonian dominant (...)

The European Commission conditionally clears a merger leading to the creation of the largest European producer of generic medicines (Hexal/Eon Labs)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Mergers — Main developments between 1 May and 31 August 2005"* The Commission authorised the acquisition of Hexal, a German producer of generic medicines, and its US sister company Eon Labs by Novartis, in a deal which creates the largest European producer of generic medicines. The clearance (...)

The European Commission authorises an acquisition in the OTC industry creating the largest European OTC consumer health company (Roche / Bayer)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Merger control: Main developments between 1 September and 31 December 2004"* In November the Commission decided to authorise the acquisition of the worldwide Roche OTC business by Bayer in a deal which creates the largest European OTC consumer health company. The operation raised serious (...)

The US FTC requires divestiture of three brand drugs in order to grant approval to a merger between two pharmaceutical companies (Sanofi-Synthelabo/Aventis)
US Department of Justice
,
BakerHostetler (Washington)
,
Pillsbury Winthrop Shaw Pittman (New York)
In two recent decisions involving pharmaceutical mergers – Cephalon/Cima, in August 2004, and Genzyme/Novazyme, in January 2004, a divided Federal Trade Commission was accused by dissenting Commissioners of breaking with precedent and allowing acquisitions involving innovator pharmaceuticals (...)

The US FTC employs an uncommon remedy to resolve the anticompetitive concerns of a merger-to-monopoly by requiring the merged firm to license a generic form of its breakthrough cancer pain drug to a third party (Cephalon/CIMA)
US Department of Justice
,
BakerHostetler (Washington)
,
Pillsbury Winthrop Shaw Pittman (New York)
In two recent decisions involving pharmaceutical mergers – Cephalon/Cima, in August 2004, and Genzyme/Novazyme, in January 2004, a divided Federal Trade Commission was accused by dissenting Commissioners of breaking with precedent and allowing acquisitions involving innovator pharmaceuticals (...)

The Polish Competition Authority clears a merger in the pharmaceuticals sector, subject to a divestment remedy (Sanofi Synthelabo/Aventis)
Clifford Chance (Warsaw)
The operation The acquisition of Aventis by Sanofi-Synthelabo was performed by a public bid. The President of the OCCP, on 18 May 2004, cleared the merger, which led to the establishment of one of the largest pharmaceutical groups in the world (pages 3-5). The market(s) The President of the (...)

The European Commission conditionally clears a merger in the medical devices market (GE Medical Systems / Instrumentarium)
J G Associates (Brussels)
,
DG COMP (Brussels)
"Merger Control: Main developments between 1st September 2003 and 31st December 2003"* In September the Commission approved, subject to conditions, the acquisition by GE Medical Systems of the Finnish firm Instrumentarium. The proposed acquisition was notified to the Commission on 28 February (...)

The Czech Competition Office clears a merger in the chemical sector subject to termination of an exclusive cooperation and business divestiture (DSM/Roche)
Clifford Chance
The operation On the basis of the share and property purchase agreement concluded between DSM N.V. ("DSM") and Roche Holding AG, Roche Finanz AG, Roche Vitamins Inc., Roche Farma SA, Roche Pharmaholding B.V., Roche Deutschland Holding GmbH and Hoffmann - La Roche France SAS, DSM acquired (...)

The European Commission clears the acquisition of the vitamins and fine chemicals division of a Swiss pharmaceutical company by a Dutch company after a detailed investigation (Roche/DSM)
DG COMP (Brussels)
,
J G Associates (Brussels)
,
DG COMP (Brussels)
"Merger control: main developments between 1st May and 31st August 2003"* On 23 July 2003, the European Commission cleared the proposed acquisition of the Vitamins and Fine Chemicals division of Swiss company Roche by Dutch-based company DSM after a detailed investigation. The Commission had (...)

The Czech Competition Office clears in a landmark decision in phase II a merger in the pharmaceutical sector subject to several structural and behavioural remedies, including transfer and divestment of trademarks and termination of a license agreement (Zentiva/S. L. Pharma)
Clifford Chance
The operation On the basis of share transfer agreement concluded on 20 January 2003, ZENTIVA B.V. ("Zentiva") acquired 100 % of shares in S.L. PHARMA HOLDING GESELLSCHAFT M.B.H. ("SLP") and therefore gained a sole control over the company. Zentiva operates in Czech Republic mainly through (...)

The Hungarian Competition Authority clears a merger in the sector of pharmacies with a posteriori condition including limited termination of control (UTA Pharma Beteiligungs/Pharma Concept)
Lakatos, Köves & Partners (Budapest)
The operation Both UTA Pharma and Pharma Concept are trust and investment companies targeting to get indirect limited partnership in pharmacies and to finance them. The pharmacies in Hungary are established in the form of partnership with limited liability. The newly created merger would (...)

The EU Commission conditionally clears the merger of the medical ventilators, anaesthesia delivery systems and patient monitoring businesses of two German companies (Siemens / Drägerwerk)
DG Economic and Financial Affairs (ECFIN) (Brussels)
,
DG COMP (Brussels)
,
DG GROW (Brussels)
"Merger Control: Main developments between 1st January 2003 and 30th April 2003"* On 30 April 2003, the Commission approved, subject to conditions, the merger of the medical ventilators, anaesthesia delivery systems and patient monitoring businesses of Siemens AG and Drägerwerk AG, two German (...)

The Slovak Antimonopoly Office approves a merger in the sector of pharmacy with remedies including the divestiture of a business unit designated for a production of specific medicaments (Pfizer/Pharmacia)
Čechová & Partners
The operation By a decision dated 23 04 2003, the Antimonopoly Office of the Slovak Republic approved the acquisition of exclusive control of the undertaking Pfizer over the undertaking Pharmacia by a merger between the 100% subsidiary of Pfizer - company Pilsner Acquisition Sub Corp. and (...)

The European Commission conditionally clears a merger in the pharmaceutical sector creating the largest pharmaceutical company in the world in terms of sales and R&D spending (Pfizer/Pharmacia)
DG Economic and Financial Affairs (ECFIN) (Brussels)
,
DG COMP (Brussels)
,
DG GROW (Brussels)
"Merger Control: Main developments between 1st January 2003 and 30th April 2003"* The European Commission authorised, subject to conditions, the acquisition of Pharmacia Corporation (Pharmacia) by Pfizer Inc. (Pfizer) in a deal creating the largest pharmaceutical company in the world in terms (...)

The US FTC imposes divestiture of assets for one product and licensing of patents for two other products prior to approving a merger in the pharmaceuticals industry (Amgen / Immunex)
Akin Gump Strauss Hauer & Feld (Dallas)
Amgen Inc. and Immunex Corporation entered into a consent decree with the FTC on September 3, 2002 in order to proceed with the merger of the two pharmaceutical giants. To obtain clearance from the FTC, Amgen and Immunex agreed to divest Immunex’s business concerning the production of one (...)

The Hungarian Competition Office approves an acquisition in the pharmacy market with remedies including non-discrimination obligations and reporting commitments (Hungaropharma / Richter Gedeon)
Lakatos, Köves & Partners (Budapest)
The operation The HCO authorized the acquisition of Hungaropharma by the consortium of Richter, Egis, Béres and Magyar Gyógyszer. Hungaropharma is owned by the Hungarian State. A sale and purchase agreement ("Agreement") was concluded by and between APV Rt and the Consortium. According to the (...)

The Hungarian Competition Office clears a merger in the pharmacies wholesale market sector with remedies including non-discrimination and reporting obligations (Hungaropharma)
Lakatos, Köves & Partners (Budapest)
The operation The HCO authorized the acquisition of Hungaropharma by the consortium of Richter, Egis, Béres and Magyar Gyógyszer. Hungaropharma is owned by the Hungarian State. A sale and purchase agreement ("Agreement") was concluded by and between APV Rt and the Consortium. According to the (...)

The European Commission clears an acquisition in the markets for crop protection, professional pest control and animal health products subject to substantial divestitures (Bayer/Aventis/Crop Science)
DG Economic and Financial Affairs (ECFIN) (Brussels)
,
DG COMP (Brussels)
,
Financial Conduct Authority (FCA) (London)
"Merger Control: Main developments between 1st January 2002 and 30th April 2002"* The Commission decided to clear Bayer‘s acquisition of Aventis Crop Science (ACS), subject to substantial divestitures. As initially notified, the operation would have led to the creation or strengthening of (...)

The German Competition Authority prohibits a planned merger that would have led to firms involved gaining dominant positions on certain markets in the wholesale pharmaceutical sector (Sanacorp / Andreae-Noris Zahn)
German Competition Authority (Bonn)
Bundeskartellamt prohibits Sanacorp/Andreae-Noris Zahn concentration* The Bundeskartellamt has prohibited the concentration plans of Sanacorp e.G. Pharmazeutische Grosshandlung, Planegg, (turnover in Germany approximately DM 3.89 billion) to acquire a majority holding in Andreae-Noris Zahn AG, (...)

The Turkish Competition Authority clears a merger in the pharmaceuticals sector subject to limitation of the non-compete clause (Abbott-BASF)
Esin
The operation Abbott is a USA based public company which is active in the field of discovery, improvement, manufacture and marketing of certain pharmaceutical products. Abbott holds 99.9% of its Turkish subsidiary which is also active in the pharmaceutical sector. BASF is a German public (...)

The European Commission approves, subject to remedies, a joint venture between UK and German pharmaceuticals companies (Smith & Nephew/Beiersdorf)
DG Economic and Financial Affairs (ECFIN) (Brussels)
,
DG COMP (Brussels)
,
Financial Conduct Authority (FCA) (London)
"Merger Control: Main developments between 1st January 2001 and 30th April 2001"* At the end of January the Commission gave regulatory clearance to a proposed joint venture between British undertaking Smith & Nephew plc and Beiersdorf AG of Germany after the parties made substantial (...)

The Turkish Competition Authority cleared with remedy a merger in the pharmaceuticals sector subject to remedies, including transfer of licences to third parties (Glaxo-SmithKline)
Esin
The operation Prior to the transaction Glaxo was a public company which was engaged in research, development, production and marketing in the pharmaceuticals sector. Glaxo had a Turkish subsidiary named Glaxo Wellcome Ilaclarý San. A.S. (“Glaxo Turkey”) through which Glaxo carried out its (...)

The Turkish Competition Authority clears a merger in the chemicals sector subject to transfer of products licenses to a third party (Glaxo-SmithKline)
Esin
The operation Prior to the transaction Glaxo was a public company which was engaged in research, development, production and marketing in the pharmaceuticals sector. Glaxo had a Turkish subsidiary named Glaxo Wellcome Ilaclarý San. A.S. (“Glaxo Turkey”) through which Glaxo carried out its (...)

The European Commission clears an acquisition in the crop production industry (Astra Zeneca/Novartis)
European External Action Service (Brussels)
,
Financial Conduct Authority (FCA) (London)
,
DG COMP (Brussels)
"Merger Control: main developments between 1st May 2000 and 31st August 2000"* In this operation, which will lead to the world.s leading crop protection business, Astra-Zeneca, itself created through the merger between Astra AB and Zeneca Group PLC in spring 1999, and Novartis, resulting from (...)

The European Commission approves a merger leading to the creation of one of the largest pharmaceutical company (Pfizer/Warner-Lambert)
European External Action Service (Brussels)
,
Financial Conduct Authority (FCA) (London)
,
DG COMP (Brussels)
"Merger Control: main developments between 1st May 2000 and 31st August 2000"* Resulting from the merger between Glaxo Wellcome and SmithKline Beecham, the new company, Glaxo SmithKline, will be the world’s biggest pharmaceuticals firm with 7.3% of global sales. The deal raised concerns about (...)

The European Commission conditionally approves a merger in the pharmaceutical sector leading to the creation of the world’s largest pharmaceuticals company (Glaxo Wellcome/SmithKline Beecham)
European External Action Service (Brussels)
,
Financial Conduct Authority (FCA) (London)
,
DG COMP (Brussels)
"Merger Control: main developments between 1st May 2000 and 31st August 2000"* Resulting from the merger between Glaxo Wellcome and SmithKline Beecham, the new company, Glaxo SmithKline, will be the world’s biggest pharmaceuticals firm with 7.3% of global sales. The deal raised concerns about (...)

The European Commission revokes its decision to clear a merger in the pharmaceutical sector because the clearance was based on incorrect information (Sanofi/Synthélabo)
European Commission - DG TRADE
,
European Commission - DG TRADE
"Mergers: Recent developments and important decisions"* Pursuant to Article 6(3)(a) of the EC Merger Regulation, the European Commission revoked its decision of 15 March 1999, which cleared the merger of Sanofi, controlled by the Elf-Aquitaine group and Synthélabo, controlled by the L’Oréal (...)

The European Commission requires for the first time remedies to clear a concentration in the pharmaceutical sector (Astra/Zeneca)
European Commission - DG TRADE
,
European Commission - DG TRADE
"Mergers: Recent developments and important decisions"* The decision in Astra/Zeneca marks the first time in the pharmaceutical sector where commitments were required to clear the concentration. In view of the ongoing consolidation of the pharmaceutical industry, such situations may become (...)

The EU Commission approves the creation of a joint venture in the pharmaceutical sector between a French company and a US company (Sanofi / Bristol-Myers Squibb)
DG COMP (Brussels)
"Mergers : other developments"* The Commission approved the creation of a joint venture in the pharmaceutical sector between the French company Sanofi and the US company Bristol-Myers Squibb. The purpose of the cooperation is the development, manufacture and commercialisation of two new (...)

The European Commission clears, subject to divestiture, a merger in the pharmaceutical industry (Hoffmann-La Roche/Boehringer Mannheim)
European Commission - DG TRADE
,
DG COMP (Brussels)
"Mergers Recent important decisions" In September 1997, the Swiss pharmaceutical company Hoffmann-La Roche proposed to acquire Corage Ltd., ultimate parent company of the Boehringer Mannheim Group (BM). After a preliminary appreciation of the case the Commission concluded that in clinical (...)

The European Commission approves, subject to remedies, a merger in the health care, animal feed, crop protection and seeds sectors (Ciba-Geigy / Sandoz)
DG GROW (Brussels)
"Mergers : Summary of the most important recent developments"* On 17th July, after four months of extensive investigations, the Commission approved the proposed merger between Ciba-Geigy and Sandoz into Novartis. The decision was granted under the condition that the parties comply with an (...)

The EU Commission refers a proposed merger in the wholesale and retail of pharmaceutical products to the competent UK authorities (GEHE/Lloyds)
DG COMP (Brussels)
"Mergers : Summary of the most important recent developments"* On 22nd March the Commission decided that the public bid by GEHE for Lloyds the Chemists should be referred to the competent United Kingdom authorities for further investigation. Through its AAH subsidiary, GEHE is currently the (...)

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues